Graduation arc · Alzheimer’s Cure Discovery · Invent Deposition #3325 (2017) → Alzheimer’s Mechanism Analysis — Proof of Function #1

The 2017 seed-line

In 2017, the entry that became Alzheimer’s Mechanism Analysis — Proof of Function #1 was written down as Invent Deposition #3325:

“My thought to amplify the core is by multiplying the board and amp mechanism operations and connections during a core connection and relay amplitude marker a starting point that has a reciprocating point to relay.”— © 2017 Christopher Gabriel Brown

What changed between 2017 and the product on the shelf

The 2017 entry pointed at the mechanism in plain words, not at a marketable molecule. Between then and the Proof of Function on the storefront today, the work hardened into a structured mechanism-analysis grid: candidate aggregation pathways (tau and amyloid families), neuroinflammation drivers, and a closed-loop survey methodology that ranks each candidate against the same scoring rubric used across the cure-discovery portfolio. The grid is what a partner team receives under an evaluation licence; the underlying patent-pending filings move with full acquisition. Design targets only — no warranted clinical outcome.

Where it sits in the four-step framework

• Proof of Function — this article’s SKU. A working write-up against representative inputs; available for licensing review at Alzheimer’s Mechanism Analysis — Proof of Function #1.
• Tech Validation — bench data and reproducibility under an evaluation licence.
• Eval Licence — supervised use of the IP package by a partner team.
• Full Acquisition — the patent application, prior-art binder, and prosecution file transfer in full.

→ Open the Proof of Function: Alzheimer’s Mechanism Analysis — Proof of Function #1

Provenance: published 2017 in the Invent Depositions collection (Invent Deposition #3325); part of an intellectual-property portfolio with U.S. patent applications dating to 2012; independently timestamped by the Internet Archive. Patent-pending. Design targets, not warranted performance. First to market — documented public offering, not a determination of patent priority.